FDA advisors reject Biogen's ALS drug for rare and aggressive form of the disease

FDA advisors voted against Biogen's investigational ALS drug, which could become the first to target a genetic cause of the disease.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.